Background: Pre-existing mitral pathology is common in patients undergoing continuous-flow left ventricular assist device implantation. We sought to investigate whether concurrent mitral repair confers any advantage.
Results: The mean age was 56.8 years and 25 (21.5%) were women. Patients in Group A were more likely to have undergone destination therapy (48.1% vs 11.1%; P<.001) and had a greater cardiopulmonary bypass time (125 vs 89 minutes; P<.001) than did patients in Group B. Longitudinal analysis using a generalized mixed-effects model demonstrated the odds of developing moderate or severe MR during device support were 86% lower for Group A patients (P <.001). Among those who were discharged alive, 9 (8.6%)-consisting of 1 (2.2%) in Group A and 8 (13.6%) in Group B (P ¼ .039)-developed late right heart failure requiring a total of 13 readmissions (0.03 vs 0.15 readmissions per patient-year; P ¼ .011). Multivariable competing risks regression revealed mitral repair to be a protective factor (hazard ratio, 0.16; 95% confidence interval, 0.03-0.94; P ¼ .042) for late right heart failure occurrence.
Conclusions:
Concurrent mitral repair appears to be efficacious in controlling MR after device implant. The fact that repaired patients developed late right heart failure less frequently than did patients without repair challenges the notion that concurrent mitral repair is unwarranted. (J Thorac Cardiovasc Surg 2017;154:1303-12)
Late right heart failure occurrence in patients with mitral repair versus without repair.
Central Message
Concurrent mitral repair appears to be efficacious in controlling mitral regurgitation after device implant with less frequent late right heart failure compared with patients without repair.
Perspective
Pre-existing mitral pathology is common in patients receiving a continuous-flow left ventricular assist device, whereas clinical implication of concurrent repair is unknown. Concurrent repair appears to be efficacious in controlling mitral regurgitation postimplant with less frequent late right heart failure compared with patients without repair, challenging the notion that concurrent repair is unwarranted.
See Editorial Commentary page 1313.
With the evolution of technology and patient management, continuous-flow left ventricular assist device (CF-LVAD) use has grown rapidly. 1 In this context, the management of pre-existing valvular lesions has become a subject of interest. The management of native valve dysfunction in CF-LVAD recipients has been discussed mainly with regard to aortic and tricuspid valves. [2] [3] [4] By contrast, pre-existing mitral pathology and its clinical influence has not been extensively investigated, despite being the most prevalent valvular pathology. 5 The mechanism of mitral regurgitation (MR) in most patients receiving device therapy is functional, resulting from tethering of the leaflets secondary to left ventricular (LV) dilatation and a change in geometry from an elliptical to spherical shape. 2, 6, 7 With device decompression, LV dimensions decrease and allow mitral leaflets to coapt, making MR insignificant in most patients. 8 Furthermore, the severity of pre-existing MR does not necessarily provide independent prognostic information. 5 The current consensus statement does not recommend concomitant mitral interventions, regardless of severity, unless there is expectation of ventricular recovery. 9 However, it is of critical importance to note that previous studies were lacking a surgical control group. Therefore, it remains unclear whether patients with pre-existing MR would benefit from repair at device insertion. We have reviewed our experience of CF-LVAD implantation with and without mitral repair to demonstrate the outcomes and ultimately elucidate its clinical implications.
METHODS
The Columbia University Institutional Review Board approved all aspects of the study. 
Patients and Study Design

Assessment of MR
Details of our protocol have been reported elsewhere. 10, 11 In brief, serial transthoracic echocardiography and intraoperative transesophageal echocardiography evaluations, reviewed by the same echocardiographers at our institution, were performed in all patients. The presence of MR was determined at baseline before device implant, and until time of last follow-up or censoring event as clinically indicated. Each valve was evaluated visually in the parasternal short-and long-axis views by transthoracic echocardiography and was graded as none, trace, mild, mild-moderate, moderate, moderate-severe, and severe on an interval scale based on the color flow jet according to the recommendations of the American Society of Echocardiography. 12 Regarding speed optimization, we followed the current recommendations 13 to ensure middle interventricular septum position and intermittent aortic valve opening while attempting to maintain less-than-mild MR.
Right Heart Failure Definition and Management
Right heart failure (RHF) during index hospitalization was captured using the Interagency Registry for Mechanically Assisted Circulatory Support definition.
14 Late RHF was defined as RHF requiring rehospitalization after indexed hospital discharge and medical/surgical treatments, including strengthening of diuretics, inotropic support, and right ventricular assist device (RVAD). 15, 16 Patients who were hospitalized due to symptoms of heart failure routinely underwent interrogation of the device and hemolysis workup to rule out device failure and thrombosis, implantable cardioverterdefibrillator/pacemaker interrogation to identify presence of arrhythmia that may have exacerbated RHF, and echocardiography for optimization of pump speed. Initial medical management included intensification of diuretic therapy. Patients with severe RHF, as defined by the presence of end-organ dysfunction, underwent right heart catheterization, with inotropic therapy initiated if needed. In patients with medically refractory RHF, RVAD implantation was then considered. 15, 16 Detection of late RHF was based on clinical findings, including edema, weight gain, ascites, and jugular venous distention. Heart failure related to device failure, such as device thrombosis, inflow and outflow obstruction, or drive-line fracture, was not considered late RHF.
Indications and Operative Technique of Mitral Repair
The indication for mitral repair is pre-existing MR greater than moderate. The decision to perform a repair was based on clinical characteristics in each patient, essentially bridge-to-transplant patients with anticipated prolonged device support (such as blood type O, large body size with body mass index [BMI] > 35) and patients with destination therapy intent at time of device insertion.
Tricuspid repair was performed for moderate or greater tricuspid regurgitation. 4 Tricuspid ring annuloplasty was the first choice of procedure. In the case of severe leaflet tethering or destruction, tricuspid replacement was performed with a bioprosthetic valve.
Annuloplasty. This is our preferred approach for repair. After establishing CPB with standard aortobicaval cannulation, mitral repair was performed with a beating heart. A standard right-sided left atriotomy was made. A commercially available annuloplasty ring (Table 1) was implanted using interrupted 2-0 polyester sutures placed circumferentially around the annulus in mattress fashion ( Figure E1, A) . The annulus was usually undersized by 2 sizes. The atriotomy was then closed.
Edge-to-edge repair. Edge-to-edge repair (Alfieri stitch) 17 was chosen when other concomitant valve repair/other procedures were performed or ring annuloplasty was not possible due to severe mitral annular calcification. For instance, when concomitant aortic valve repair was performed, CPB was established with the standard aortoatrial cannulation followed by aortic crossclamping and cardioplegia administration. A central edge-to-edge stitch (Alfieri stitch) using 2-0 polyester sutures with or without pledgets was placed approximately 10 mm away from the free edges of A2 and P2 through the transverse aortotomy ( Figure E1 , B). The aortic valve repair was then performed. The rest of the procedure was conducted in the usual fashion 18 after aortotomy closure and unclamping. This repair was also performed through the LV apex after coring for the inflow cannula placement or transseptally when concomitant tricuspid procedure was performed.
Statistical Analysis
Continuous variables were expressed as mean AE 1 standard deviation. Categorical variables were presented as proportions and absolute numbers. Differences were detected using c 2 or Fisher exact test for categorical and the Mann-Whitney U or Student t test for continuous variables. The survival was estimated using Kaplan-Meier method and compared with log-rank test. Patients were censored for transplant or device explant. Preimplant clinical parameters were analyzed to determine contributing factors for late RHF using the competing risks regression methods of Fine and Gray 19 to account for competing events, which were death and transplant. For multivariable analysis, variables with a P value .25 on univariable analysis were included into a final model. In addition, due to the small number of events, concomitant tricuspid repair and baseline pulmonary vascular resistance were also included as surrogates of baseline right ventricle (RV) function by clinical judgment. Results are presented as hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). For longitudinal data analysis, a mixed-effects logistic regression model with a logit link was employed to assess the association between treatment and MR severity. 20 The final models included fixed effects for treatment group, time (continuous scale), and a random effect to account for within-subject variation. To satisfy the linearity assumption, a log transformation was applied to the time variable. In addition, a time 3 group interaction was tested, but found to be statistically nonsignificant. All P values were results of 2-tailed tests. The statistical analysis was performed using SPSS 22.0 (IBM-SPSS Inc, Armonk, NY), Stata 14.2 (StataCorp, College Station, Tex), and SAS 9.4 (SAS Institute Inc, Cary, NC).
RESULTS
Patient Demographic Characteristics
Patient demographic characteristics are shown in Table 2 . The mean age was 56.8 years and 25 (21.7%) were women. Patients in Group A were more likely to be planned for destination therapy than were patients in Group B. There were more patients with BMI > 35 in Group A, whereas the mean BMI is indifferent. Furthermore, concurrent mitral repair was more often performed in relatively recent patients, with the first in 2007 (there were no destination therapy patients before 2007 in the present study cohort). Otherwise, the groups both displayed similar clinical characteristics. The baseline echocardiographic variables are further displayed in Table 2 . The severity of MR was similar and moderate or greater tricuspid regurgitation was common in both groups. Table 1 illustrates the intraoperative data. Implanted device brand and the frequency of other concomitant procedures performed were similar. Subjects in Group A had a greater CPB time than did individuals in Group B. In contrast, the dose of vasoactive drugs, as represented by the vasoactive-inotropic score 21 and blood product use, were comparable between groups.
Intraoperative Data
Regarding the repair method, 34 (65.4%) received a ring annuloplasty, 15 (28.9%) received an edge-to-edge repair, and 2 (3.9%) received a repair with other . The median annuloplasty size was 28 mm (interquartile range, 26-32 mm). As for edge-to-edge repair, almost half were performed through the LV apex. The CPB time was significantly longer in patients with annuloplasty compared with others, but not with isolated ring annuloplasty versus isolated edge-to-edge repair (Table 1) .
Adverse Events and Survival
Early postoperative outcomes and adverse events were summarized in Table E1 . There was no difference regarding early postoperative complications between groups. Among discharged patients alive with either HeartMate II or HeartWare device, predischarge pump speed in the repaired patients supported with HeartMate II was significantly lower than that of nonrepaired patients with HeartMate II, whereas no difference among patients with HeartWare between groups. Regarding overall adverse events, more frequent RHF, which is attributable to late RHF occurrence, was observed in Group B (Figure 1, A and B) , whereas RHF during the index hospitalization was comparable between groups (Table E1) . Overall, 5 (9.6%) in Group A and 3 (4.8%) in Group B received an RVAD. There was no difference regarding the occurrence of other adverse events ( Figure 1 , A and B, Figure E2 , A and B, Figure E3 , A and B, and Figure E4 ). The estimated on-device survival at 2 years was 79.9% (6.5%) and 68.8% (11.1%) (P ¼ .83), and the overall survival at 2 years was 79.1% (6.0%) and 85.5% (4.5%) (P ¼ .40) in Group A and B, respectively (Figure 2 and Figure E5 ).
Comparison of Postimplant MR Between Groups
Significant postimplant residual MR was defined as at least moderate MR despite medical therapy, device decompression, and pump speed optimization. A total of 429 postimplant echocardiographic studies were available. Table E2 demonstrates the number of echocardiographic studies remaining at each time point. Longitudinal changes in MR grades over time at time of/after index hospital discharge in each group are shown in Figure 3 . At time of discharge, no patients in Group A had residual MR, whereas 20% in Group B (P <.001) did. Approximately 30% of patients in the nonrepair group demonstrated significant residual MR consistently across the follow-up periods up to 2 postdevice years. MR appeared to be well controlled regardless of surgical technique (ring annuloplasty vs edge to edge). Furthermore, the longitudinal analysis using generalized mixed effects model showed the odds of developing a moderate/severe MR were 86% lower for patients who underwent repair versus those who did not (P <.001) ( Table 3) .
Contributing Factors for Late RHF and Posttransplant Survival
Among 105 patients (46 repaired and 59 nonrepaired) who were discharged alive, 9 (8.6%), consisting of 1 (2.2%) in Group A and 8 (13.6%) in Group B (P ¼ .039), developed late RHF requiring a total of 13 readmissions (0.03 vs 0.15 readmissions per patient-year; P ¼ .011). All patients received intensified diuretic therapy, 4 received inotropic therapy, and 1 (1 out of 8; 12.5%) in Group B required an RVAD implantation. Further subgroup comparison stratified by the presence of tricuspid repair was also performed. The incidence of late RHF in each group was 3.0% (mitral repair alone; n ¼ 33), 0% (mitral þ tricuspid repair; n ¼ 10), 11.1% (tricuspid repair alone; n ¼ 18), and 12.5% (no mitral or tricuspid repair; n ¼ 40), respectively (P ¼ .34).
Clinical parameters before/at device insertion were analyzed to identify contributing factors for late RHF occurrence. Multivariable competing risks regression analysis revealed that blood urea nitrogen was a contributing factor (HR, 1.21 per 5-point increase; 95% CI, 1.03-1.42; P ¼ .022), whereas mitral repair was a protective factor (HR, 0.15; 95% CI, 0.028-0.85; P ¼ .031) ( Table 4) . A list of variables entered in the analysis is shown in Table E3 .
Among those 9 patients who developed late RHF, 6 patients underwent bridge to transplant. The 2-year survival after transplant was 33.3% among these 6 patients. Two died of primary graft dysfunction/multiorgan failure and other two died of sepsis/multiorgan failure. In contrast, the 2-year survival among transplanted patients who did not experience late RHF was 93.3% (42 out of 45).
DISCUSSION
The fact that late RHF was observed less frequently in the repaired patients, even compared with nonrepaired patients with baseline severe MR, clearly challenges the notion that concurrent mitral repair is unwarranted. We speculate that more controlled postimplant MR enables less challenging volume management postoperatively. Furthermore, having more controlled MR would be safer in cases of unexpected device failure (Video 1).
In contrast to the attention paid to aortic/tricuspid disease in patients with a CF-LVAD, mitral pathology has received less attention for surgical repair largely due to the reduction in left ventricular end-diastolic diameter and MR severity following device insertion. 2, 8, 22 Furthermore, no previous studies have demonstrated uncorrected MR to be associated with worse survival. Stulak and colleagues 22 reported on 491 patients among whom 189 had greater-thanmoderate MR and 302 had moderate MR or less. There was more favorable survival in patients with severe preimplant MR, suggesting lack of value of surgical repair. However, neither surgical control nor postimplant MR data were provided in their study. Another study with a smaller cohort, again without a surgical control group, demonstrated Despite lack of surgical control groups across all of these studies, there has been a general consensus that preexisting MR does not require repair at device implantation, irrespective of its severity. Consequently, most centers presently avoid any procedures on regurgitant mitral valves. Meanwhile, there have been a few studies describing concurrent mitral repair from small cohorts of patients. Russo and colleagues 23 examined the outcomes of transapical edge-to-edge mitral repair on 19 patients who underwent CF-LVAD placement. Taghavi and colleagues 24 reported on 57 patients among whom 18 (32%) received a repair and 3 (5%) received a replacement. Although sample size and lack of clinical details limit interpretation of these study results, both demonstrated acceptable postoperative morbidity. Moreover, the latter showed greater postimplant decrease in pulmonary vascular resistance in the repair group. 24 More recently, Tanaka and colleagues 25 demonstrated that patients whose MR was corrected with valve repair or replacement had significantly better hemodynamic profiles postimplant compared with patients whose MR spontaneously resolved with CF-LVAD implantation alone.
In addition, heart failure-related readmission rate was observed less frequently in the repaired group. Their results are partially in line with findings in the present study.
Although the severity of MR has been demonstrated to regress without repair, CF-LVAD unloading may not be sufficient to counteract functional MR in a subset of patients. Kitada and colleagues 2 reviewed 82 patients who underwent CF-LVAD insertion after excluding patients with organic lesions. More than 30% of patients continued to have significant MR despite device support. Although MR usually decreases with higher speeds, it appears that preoperative posterior displacement of mitral leaflets is associated with persistent MR. Their results are compatible with the present study, in which 20% to 35% of patients in the nonrepair group demonstrated persistent MR postimplant.
Pump speed is determined based on optimal LV unloading and severity of MR while avoiding complications related to high pump flow. The MR degree significantly varies with pump speed and hemodynamic parameters during echocardiography. 11 Furthermore, there is a trade-off relationship between pump speed and RV function. By increasing pump speed, which is used to reduce MR degree, RV function and aortic valve opening can be compromised. The degree of septal deviation may predict the development of RV failure during CF-LVAD support. 26, 27 With reduced LV pressures, bowing of the interventricular septum away from the RV into the decompressed LV can alter RV shape and size and reduce the efficiency of RV contraction. 25 The RV may be further challenged by the increased preload provided by the device effect on increased systemic blood flow, which is increased at higher pump-speed settings. 28 Again, pump speed has such dynamic characteristics determined by multiple factors. Optimal pump speed widely varies in each individual and therefore the mean pump speed as a group (repair or nonrepair) has little clinical relevance, although repaired patients with a HeartMate II device demonstrated lower mean pump speed in the present study. We suspect the relatively small sample size of the HeartWare cohort (11 patients in Group A and 7 patients in Group B) might be insufficient to detect significant differences in pump speed. We postulate mitral repair might have lowered pump speed, which would have been the amount of speed to be added to suppress MR degree. Uriel and colleagues 11 conducted a study to evaluate the utility of ramp tests for assessing ventricular decompression in HeartWare ventricular assist device patients. 11 The interaction of left ventricular end diastolic diameter with mitral repair suggests that ventricular geometry influences the device unloading properties. By decreasing the size of the mitral annulus, the mitral repair amplifies the effects of ventricular decompression. The authors suggested mitral repair might be indicated if lower speeds are necessary to preserve aortic valve integrity or maintain pulsatility within the peripheral circulation. The optimal repair method remains unclear. In the present study, 2 techniques, consisting of annuloplasty and edge-toedge repair, were performed. Although the technical feasibility and durability of each technique appeared acceptable, no conclusion could be drawn from the data regarding the choice of repair technique. The criticism edge-to-edge repair alone without annuloplasty is suboptimal durability 17 in non-CF-LVAD settings. On the contrary, there is a paucity of data specifically related to patients supported by CF-LVAD. In addition, in cases of severe annular calcification annular manipulation should be avoided. Our data confirmed the midterm durability of concurrent edge-toedge repair in patients who underwent CF-LVAD insertion. Although an advantage of these repair techniques includes procedural simplicity, concurrent mitral repair is not without risk. In fact, CPB time was significantly greater in the repair cohort. However, bleeding, blood product use, and vasoactive-inotropic score were similar. Additionally, on-device and overall survival were comparable between groups.
Study Limitations
First, our investigation is limited by the retrospective nature. Second, the serial follow-up echocardiographic studies, which can be often influenced by hemodynamic parameters, were performed in a variety of clinical settings such as in the intensive care unit and outpatient clinic. Third, the decision for repair was made by surgeons based on various clinical characteristics and repair technique in each patient was not selected randomly, introducing further selection bias into the results and making our conclusion not convincing. Furthermore, there were no data correlating repaired/nonrepaired patients with functional capacity testing or hemodynamic parameters due to lack of a postimplant cardiac catheterization. Fourth, many underwent concomitant aortic/tricuspid valve repairs in addition to mitral repair. Lastly, mitral repair was more frequently performed in relatively recent patients simply because there were few destination therapy patients before 2007 in the present study population. Although these potential confounders, including year of device implantation and other valve repairs, were all entered into the multivariable analysis and demonstrated no association with late RHF. Clinical effect by these factors to the outcomes could not be completely eliminated.
CONCLUSIONS
Concurrent mitral repair, irrespective of technique, appears to be durable in controlling MR postdevice implant. Although this study has a number of limitations, the fact that mitral repair was associated with less frequent occurrence of late RHF, which appears to be a significant factor for worse posttransplant survival, 15 is particularly noteworthy, cautioning against the concept that concurrent mitral repair is unnecessary. Considering our observation, further studies are truly needed to validate our results and clarify the unanswered questions in this society. 
